-
The pharmacy's strictest inspection is here
Time of Update: 2021-12-08
The "Detailed Rules" clearly requires that the provincial drug regulatory bureau (hereinafter referred to as the provincial bureau) conduct related inspections for drug retail chain headquarters, third-party drug online trading platforms, drug wholesale companies, drug manufacturers and other units, and the provincial bureaus shall check the drug safety risks Take effective risk control measures to organize the investigation and punishment of the above-mentioned corporate violations of laws and regulations and major cross-regional violations of laws and regulations .
-
Fierce Biotech's 2021 biopharmaceutical Waterloo event inventory
Time of Update: 2021-12-08
Last year the company’s hype about the 3-phase leronlimab trial missed its primary and all major secondary endpoints, but the company borrowed from COVID-19 gimmicks, and its stock price continued to rise in the process .
-
Domestic orphan drug giant joins hands with Pfizer to jointly develop breast cancer treatment
Time of Update: 2021-12-08
Specifically, the two parties will jointly develop Lisaftoclax (APG-2575), a selective Bcl-2 inhibitor of Ascent Pharmaceuticals, combined with Pfizer's CDK4/6 inhibitor, Aiboxin (pibacillil), for the treatment of relapsed and locally advanced stages.
-
Market forecast: The domestic antibiotic industry as a whole may maintain greater demand in the next few years
Time of Update: 2021-12-08
Data show that in recent years, under the implementation of antimicrobial control measures such as the graded management of antibiotics, the scale of China's antibiotics market has grown slowly .
-
Since November, a number of domestically produced Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-12-08
Prior to this, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng has also received CDE approval for the marketing application of Brainshang Lesheng Granules submitted by the new drug category 1.
-
A pharmacy lost 500,000 yuan due to illegal sales of prescription drugs
Time of Update: 2021-12-08
However, during the epidemic prevention period, pharmacies who sell prescription drugs in violation of regulations are often severely punished .
In response, the two pharmacies had their business licenses revoked for failing to sell drugs to confirmed cases in accordance with regulations .
-
GlaxoSmithKline first-in-class antibiotics apply for clinical application in China
Time of Update: 2021-12-08
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn November 11, the CDE official website showed that the clinical application of GSK's new antibiotic Gepotidacin tablets was accepted by the State Food and Drug Administration .
-
GSK is developing a new hepatitis B drug at the CIIE!
Time of Update: 2021-12-08
From the launch of the first chronic hepatitis B oral antiviral drug in China to the launch of the oral drug "Veride" in 2014, Huang Jingxuan, head of GSK China’s core prescription drug business department, introduced, “GSK is committed to providing the most innovative drugs for Chinese hepatitis B patients to help improve China's hepatitis B prevention and treatment level .
-
What you have to know about medicinal excipients with more than 100 billion growth space for lips and teeth
Time of Update: 2021-12-08
US FDA:Pharmaceutical excipients are inactive ingredients in preparations other than the main drug (API)"Japanese Pharmacopoeia":In addition to the specially specified substances, in order to ensure the properties and quality of the preparations and improve the compliance of the preparations during the storage process, excipients, stabilizers, preservatives, buffers, correctives, and auxiliary agents may be added as needed.
-
A batch of listed pharmaceutical companies issued an announcement on November 10, concerning share reduction, cooperation, etc.
Time of Update: 2021-12-08
704 million repurchased shares Meirui Health International announced that on November 10, 2021, the company cancelled 22.
Yan'an Bikang announced that the company and Guanyou Capital will "hand in hand", and the two parties intend to reach a cooperative relationship.
-
Domestic new drug research and development has entered a period of rapid development, and pharmaceutical companies have set off a "financing fever"
Time of Update: 2021-12-08
Recently, Zhimeng Pharmaceutical, a chronic liver disease treatment drug developer, announced that it has completed 350 million yuan in round B financing.
-
Rich pipelines and reasonable gradients... Domestic innovative giant pharmaceutical companies are concerned
Time of Update: 2021-12-08
Among them, the research and development expenses of Hengrui Pharmaceuticals in the first three quarters increased by nearly 24% year-on-year, reaching 4.
For example, 33 pharmaceutical companies, such as Guofa, Dashenlin, and Guangzheng Ophthalmology, experienced a year-on-year growth rate of over 100% in R&D expenses in the first three quarters .
-
The joint development of new drugs by domestic and foreign pharmaceutical companies has become the norm in the industry
Time of Update: 2021-12-08
For multinational pharmaceutical companies’ brands choosing Chinese pharmaceutical companies to develop new drugs together, the industry believes that this is mainly related to the continuous expansion of my country’s pharmaceutical market and the continuous improvement of pharmaceutical companies’ innovation capabilities.
-
People’s health awareness continues to increase, and medications for mental disorders continue to grow
Time of Update: 2021-12-08
The data shows that the total size of the mental disorder drug market in sample hospitals has continued to grow.
It is predicted that in 2021, the total size of the drug market for mental disorders in China's sample hospitals may reach 6.
-
Phase IIb China study of ADC drug targeting TROP2 triple-negative breast cancer reaches its primary endpoint
Time of Update: 2021-12-08
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 11, Genting Shinyao and Gilead Sciences jointly announced a phase IIb clinical trial of gosartuzumab (US trade name: Trodelvy) for the treatment of metastatic triple-negative breast cancer (TNBC) (EVER-132-001) Reached its primary endpoint of overall response rate (ORR) .
-
AstraZeneca's IL-5 inhibitor Fasenra was granted fast track approval by the FDA
Time of Update: 2021-12-08
S. Food and Drug Administration as a fast-track approval designation for the treatment of eosinophilic gastroenteritis with or without it.
-
With the continuous expansion of the Chinese medicine formula granule test market, two major issues cannot be ignored
Time of Update: 2021-12-08
On November 1, the State Food and Drug Administration and other departments ended the more than 20-year pilot work of traditional Chinese medicine formula granules, and officially launched the registration module of traditional Chinese medicine formula granules .
-
The "authorized introduction" innovative drug model is hot, and the product lines of local pharmaceutical companies are becoming more and more abundant
Time of Update: 2021-12-08
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods .
-
In order to ensure the safety of drugs, detailed regulations on drug supervision are issued in many places
Time of Update: 2021-12-08
Since May 28, the relevant state departments have announced the "Administrative Measures for Drug Inspection (Trial)" (hereinafter referred to as the "Measures"), which clearly requires that in order
-
Isn't the risk of drug co-production quality related to the residue content and activity?
Time of Update: 2021-12-07
If it is difficult to clean, it is easy to have the residue of the previous batch of materials, which will become an impurity in the next product .
